DiverticulitisNCT03496090
Randomized Multicentric Trial to Evaluate a Free Diet With a Progressive Diet in the Treatment of Acute Diverticulitis (DIVERDIET)
A study testing Free diet and Progressive diet in people with Diverticulitis and Acute Diverticulitis, run by Hospital General Universitario Reina Sofía de Murcia at 1 site in Spain.
Trial summary
Phase III trial is designed to demonstrate the non-inferiority of a free diet versus a progressive diet in the treatment of acute diverticulitis (AD) without complications. In this study, the effectiveness of the short-term free diet is evaluated, as well as its safety and the quality of life that is perceived in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diverticulitis, Acute Diverticulitis, Diverticulitis, Colonic
- What is being tested?
- Free diet and Progressive diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 134 participants
- Where
- 1 siteSpain
- Study dates
- 16 Apr 2018to 16 Apr 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of uncomplicated acute diverticulitis
- Adequate oral tolerance
- Good response to the first emergency treatment measures (analgesics and antibiotic therapy): improvement of pain and decrease in temperature.
- Willing to continue treatment at home under supervision.
- Accept sign informed consent.
Who cannot join
- Acute complicated diverticulitis (from grade Ib of the modified Hinchey Classification).
- No good response to the first emergency treatment measures (analgesics and antibiotics): maintenance or increase of abdominal pain, persistence of fever, oral intolerance or vomiting, clinical worsening.
- Antibiotic treatment for diverticulitis in the previous month.
- Suspicion of colorectal cancer.
- Pregnant.
- Refuses to sign informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomized Multicentric Controlled Clinical Trial of Parallel Groups to Evaluate the Non-therapeutic Inferiority of a Free Diet With a Progressive Diet, in the Treatment of Non-complicated Acute Diverticulitis
Phase III trial is designed to demonstrate the non-inferiority of a free diet versus a progressive diet in the treatment of acute diverticulitis (AD) without complications. In this study, the effectiveness of the short-term free diet is evaluated, as well as its safety and the quality of life that is perceived in front of the progressive diet.
Read the detailed description
The study will be carried out in the General Surgery and Gastroenterology Services of the following centers:
- Hospital General Universitario Reina Sofía
- Hospital General Universitario Morales Meseguer de Murcia.
- Hospital Universitario Santa Lucía de Cartagena.
- Hospital General Universitario de Elche.
- Complejo Hospitalario Torrecárdenas de Almería
All patients with increased temperature and acute abdominal pain, as well as clinical suspicion of AD, will be screened for their potential selection in the study. Basic blood tests (hemogram) and abdominal ultrasound will be performed and these guidelines will be followed: if the results indicate complicated AD, it will be excluded from the study; if uncomplicated DA is suspected, blood CRP will be requested; if CRP is less than 5 mg / dl, it will be included in the study and ambulatory treatment will be indicated; if CRP is greater than 5mg / dl, abdominal CT with intravenous contrast will be requested. Result: uncomplicated DA, it will be included in the study and it will be indicated ambulatory treatment or complicated DA, it will be excluded from the study-; those patients with uncomplicated AD, but with risk factors, hospital admission will be recommended, and they may be offered to participate in the study.
If the patient meets the criteria for admission to the study, the attending physician (surgeon on duty) will inform and invite them to participate and after signing the informed consent, their data will be collected and they will be contacted. the person of the hospital, in charge of guarding the list and randomization codes to assign him the corresponding research group: group 1 (free diet) or group 2 (progressive diet) (Annex III), - this group will be delivered of your printed diet and you will be instructed about it, as well as, to all patients, the annotations of pain control and temperature on ad-hoc sheet. The patient data will be delivered to the investigator / s of the study of each hospital, who will fill in the Data Collection Notebook (DCN) of each patient and program their controls without information of the group to which the patient has been assigned, as In this way, the consultations are carried out with blinding of the evaluator (the investigator who will do the controls will not know to which group the patient has been assigned). They will also be asked a quality of life questionnaire SF-12 (baseline) and they will be asked for a blood test with a complete blood count and CRP for the 3rd day of treatment.
Outpatients will be contacted daily by phone during the first 3 days of treatment by the study investigator and between the 3rd and 4th day will go to outpatient surgery for clinical and analytical control (1st consultation), filling in the DCN. The hospitalized patients will follow the same clinical and analytical control by the plant surgeon and the study investigator, filling in the DCN. They will be asked for new blood tests with CRP for the 7th day of treatment and, in those patients who do not have a colonoscopy in the last 12 months prior to entering the study, an endoscopic study will be requested before 60 days for confirmation of diverticular disease, filling in the DCN. They will be given a new SF-12 quality of life questionnaire that they will fill out on the 7th day of the start of the treatment. They will be cited for a new consultation (2nd consultation) to all patients (outpatients and those who have been hospitalized), 30 days of the beginning of the treatment, with new clinical control and annotation of the last analytical, as well as third and last SF-12 quality of life questionnaire, in the DCN. To conclude, patients who were asked for colonoscopy, will be cited in a final consultation (3rd) 2 months after beginning the treatment with the endoscopic result closing the study, with the last entries in the DCN.
Sample size:
To obtain a power of 80% to reject the null hypothesis Ho: that the difference of proportions p1 and p2 is lower than the non-inferiority limit of -10, and taking into account that the level of significance is 5%, assuming that the proportion of non-treatment failure in both treatment groups is 94.7%, the total number of patients expected to be included in the study is 134 patients, with an expected percentage of dropouts of 5%, which 67 patients will receive treatment through free diet and other 67 patients through progressive diet. The endpoint for the main comparison is the proportion of subjects with a lower treatment failure rate at one month (30 days) of follow-up.
Statistical treatment:
The continuous variables will be summarized using descriptive statistics: mean, standard deviation (SD), median, minimum, maximum, number of observations and number of missing observations. Non-normal continuous data will be presented as maximum, top quartile, median, lowest quartile, minimum and number of observations. The categorical variables will be described using absolute and relative frequencies.
For the comparisons between variables, the bivariate analysis will be used. The scores of each dependent variable will be compared with the independent variables using parametric statistical methods (and nonparametric when the parametric application criteria are not met). When the changes within the same treatment group are analyzed, statistical tests for related or paired samples will be used.
In the event that the variables follow the normal distribution, one or more of the following techniques will be described:
- If a variable is of a quantitative type and the other is categorical, for the comparison of the means with a dichotomous variable, the Student's t test will be used. In cases where the qualitative variable has more than 2 categories, the one-way variance analysis (ANOVA) will be used. In the analysis of the variance of a factor with repeated measures, it will be assumed that the subjects are randomly selected from normal populations with the same variance. Previously, the assumptions of independence, normality and equality of variances will be checked.
In the case that the variables do not follow the normal distribution:
- If one variable is quantitative and the other qualitative, the test to be applied will be the Mann-Whitney U test when the qualitative variable has 2 levels, and the Kruskall-Wallis test if the qualitative measurement is formed by 3 levels or plus.
- If both variables are of the categorical type, a cross-tabulation will be performed (contingency tables) using the Pearson chi-square statistic to test the independence hypothesis or the Fisher test (in 2 x 2 tables) ). An analysis of typed residuals corrected will be carried out in order to interpret the meaning of the association detected.
For the non-inferiority analysis in the main variables, a calculation will be made using the Farrington-Manning score, Miettinen-Nurminen Score and Gart-Nam Score tests, with a significance level of 0.05, and a limit of no- inferiority of 0.10. For the continuous variables, non-inferiority will be evaluated by the difference of means with the Mann-Whitney U and the Wilcoxon test.
All statistical comparisons will be made using statistical tests with a level of significance p = 0.05.
- Conditions
- Diverticulitis, Acute Diverticulitis, Diverticulitis, Colonic, Uncomplicated Diverticular Disease, Diverticulitis of Sigmoid, Diet Modification
- Being tested
- Free diet, Progressive diet
- Keywords
- Diverticulitis, Uncomplicated Diverticular Disease, Free diet, Dietary restriction, Acute Diverticulitis
- Medical subject headings
- Diverticulitis, Diverticulitis, Colonic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Free dietOther
Also called Basal diet
Free diet or free demand, being comparable to the normal or zero hospital diet
Progressive dietOther
Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
| Study group | Role | What they receive |
|---|---|---|
| Free diet | Experimental | Free diet or free demand, being comparable to the normal or zero hospital diet Receives: Other: Free diet |
| Progressive diet | Active comparator | Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day. Receives: Other: Progressive diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Success in the treatment
Absence of persistence, increase or recurrence of abdominal pain or fever, transition to a stage higher than that of the modified Hinchey classification (requiring radiological drainage and / or surgical treatment), need for hospital admission (for outpatients) and death attributed to this diagnosis.
Measured: 30 days
Secondary outcomes (5)
Pain score
The evaluation in each treatment group of pain intensity, using visual analogue scale (VAS) of pain, self-evaluated daily after dinner. Min value 0. Max value 10. Higher values represent a worse outcome.
Measured: 7 days
Body temperature
Axillary temperature curve, as a reference, by one shot every 12 hours.
Measured: 7 days
PCR value
The comparison in each treatment group of the levels of C-reactive protein (CRP).
Measured: day 0, 3 and 7
Increase in stage
Percentage of patients in each treatment group who pass to a stage higher than Ia in the Hinchey classification modified.
Measured: 30 days
Need for hospital admission
Percentage of outpatients in each treatment group who require hospital admission.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2018
- Study start16 Apr 2018
- Primary completion31 Jan 2019
- Study completion16 Apr 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (41)Papers the sponsor has linked to this study.
- Other trials for DiverticulitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is a randomized, multicentric, controlled with active comparator, parallel group, blind to the evaluator, to demonstrate the non-inferiority in the efficacy and therapeutic and safety of the free diet (group 1) compared to the progressive diet (group 2) in the treatment of uncomplicated acute diverticulitis. This study will be carried out on 134 patients with uncomlpicated acute diverticulitis. The subjects will be randomized in a 1: 1 ratio to receive treatment with progressive diet or diet at free demand. The main analysis will take place two months after the start of treatment.
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 134 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital General Universitario Reina Sofía de Murcia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jorge A Benavides Buleje, Dr., Principal investigator, Hospital General Universitario Reina Sofía de Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03496090
- Sponsor's protocol ID
- DIVERDIET
- Status last verified
- Aug 2019
- First submitted
- 27 Mar 2018
- Last updated
- 19 Aug 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Aiello F. Predictive value of serologic markers of degree of histologic damage in acute uncomplicated colonic diverticulitis. J Clin Gastroenterol. 2010 Nov-Dec;44(10):702-6. doi: 10.1097/MCG.0b013e3181dad979.
PubMed 20485187Klarenbeek BR, de Korte N, van der Peet DL, Cuesta MA. Review of current classifications for diverticular disease and a translation into clinical practice. Int J Colorectal Dis. 2012 Feb;27(2):207-14. doi: 10.1007/s00384-011-1314-5. Epub 2011 Sep 17.
PubMed 21928041Biondo S, Golda T, Kreisler E, Espin E, Vallribera F, Oteiza F, Codina-Cazador A, Pujadas M, Flor B. Outpatient versus hospitalization management for uncomplicated diverticulitis: a prospective, multicenter randomized clinical trial (DIVER Trial). Ann Surg. 2014 Jan;259(1):38-44. doi: 10.1097/SLA.0b013e3182965a11.
PubMed 23732265Reynolds IS, Heaney RM, Khan W, Khan IZ, Waldron R, Barry K. The Utility of Neutrophil to Lymphocyte Ratio as a Predictor of Intervention in Acute Diverticulitis. Dig Surg. 2017;34(3):227-232. doi: 10.1159/000450836. Epub 2016 Dec 10.
PubMed 27941316Makela JT, Klintrup K, Takala H, Rautio T. The role of C-reactive protein in prediction of the severity of acute diverticulitis in an emergency unit. Scand J Gastroenterol. 2015 May;50(5):536-41. doi: 10.3109/00365521.2014.999350. Epub 2015 Feb 9.
PubMed 25665622van de Wall BJ, Draaisma WA, van der Kaaij RT, Consten EC, Wiezer MJ, Broeders IA. The value of inflammation markers and body temperature in acute diverticulitis. Colorectal Dis. 2013 May;15(5):621-6. doi: 10.1111/codi.12072.
PubMed 23088216Nizri E, Spring S, Ben-Yehuda A, Khatib M, Klausner J, Greenberg R. C-reactive protein as a marker of complicated diverticulitis in patients on anti-inflammatory medications. Tech Coloproctol. 2014 Feb;18(2):145-9. doi: 10.1007/s10151-013-1044-5. Epub 2013 Jun 27.
PubMed 23807310Ferzoco LB, Raptopoulos V, Silen W. Acute diverticulitis. N Engl J Med. 1998 May 21;338(21):1521-6. doi: 10.1056/NEJM199805213382107. No abstract available.
PubMed 9593792Jackson JD, Hammond T. Systematic review: outpatient management of acute uncomplicated diverticulitis. Int J Colorectal Dis. 2014 Jul;29(7):775-81. doi: 10.1007/s00384-014-1900-4. Epub 2014 May 25.
PubMed 24859874Martin Gil J, Serralta De Colsa D, Garcia Marin A, Vaquero Rodriguez A, Rey Valcarcel C, Perez Diaz MD, Sanz Sanchez M, Turegano Fuentes F. [Safety and efficiency of ambulatory treatment of acute diverticulitis]. Gastroenterol Hepatol. 2009 Feb;32(2):83-7. doi: 10.1016/j.gastrohep.2008.10.005. Epub 2009 Feb 5. Spanish.
PubMed 19231679Rosado-Cobian R, Blasco-Segura T, Ferrer-Marquez M, Marin-Ortega H, Perez-Dominguez L, Biondo S, Roig-Vila JV. Complicated diverticular disease: Position statement on outpatient management, Hartmann's procedure, laparoscopic peritoneal lavage and laparoscopic approach. Consensus document of the Spanish Association of Coloproctology and the Coloproctology Section of the Spanish Association of Surgeons. Cir Esp. 2017 Aug-Sep;95(7):369-377. doi: 10.1016/j.ciresp.2017.03.008. Epub 2017 Apr 14. English, Spanish.
PubMed 28416357Pelaez N, Pera M, Courtier R, Sanchez J, Gil MJ, Pares D, Grandea L. [Applicability, safety and efficacy of an ambulatory treatment protocol in patients with uncomplicated acute diverticulitis]. Cir Esp. 2006 Dec;80(6):369-72. doi: 10.1016/s0009-739x(06)70989-7. Spanish.
PubMed 17192220Moya P, Arroyo A, Perez-Legaz J, Serrano P, Candela F, Soriano-Irigaray L, Calpena R. Applicability, safety and efficiency of outpatient treatment in uncomplicated diverticulitis. Tech Coloproctol. 2012 Aug;16(4):301-7. doi: 10.1007/s10151-012-0847-0. Epub 2012 Jun 16.
PubMed 22706731Mizuki A, Nagata H, Tatemichi M, Kaneda S, Tsukada N, Ishii H, Hibi T. The out-patient management of patients with acute mild-to-moderate colonic diverticulitis. Aliment Pharmacol Ther. 2005 Apr 1;21(7):889-97. doi: 10.1111/j.1365-2036.2005.02422.x.
PubMed 15801924Isacson D, Thorisson A, Andreasson K, Nikberg M, Smedh K, Chabok A. Outpatient, non-antibiotic management in acute uncomplicated diverticulitis: a prospective study. Int J Colorectal Dis. 2015 Sep;30(9):1229-34. doi: 10.1007/s00384-015-2258-y. Epub 2015 May 20.
PubMed 25989930
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Multicentric Controlled Clinical Trial of Parallel Groups to Evaluate the Non-therapeutic Inferiority of a Free Diet With a Progressive Diet, in the Treatment of Non-complicated Acute Diverticulitis
- ClinicalTrials.gov ID
- NCT03496090
- Acronym / sponsor ID
- DIVERDIET
- Conditions
- Diverticulitis, Acute Diverticulitis, Diverticulitis, Colonic, Uncomplicated Diverticular Disease, Diverticulitis of Sigmoid, Diet Modification
- Keywords
- Diverticulitis, Uncomplicated Diverticular Disease, Free diet, Dietary restriction, Acute Diverticulitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 134 participants (actual)
- Lead sponsor
- Hospital General Universitario Reina Sofía de MurciaUniversity, hospital or other
- Study start
- 16 Apr 2018 (actual)
- Primary completion
- 31 Jan 2019 (actual)
- Study completion
- 16 Apr 2019 (actual)
- First posted
- 12 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Phase III trial is designed to demonstrate the non-inferiority of a free diet versus a progressive diet in the treatment of acute diverticulitis (AD) without complications. In this study, the effectiveness of the short-term free diet is evaluated, as well as its safety and the quality of life that is perceived in front of the progressive diet.
Detailed description
The study will be carried out in the General Surgery and Gastroenterology Services of the following centers:
- Hospital General Universitario Reina Sofía
- Hospital General Universitario Morales Meseguer de Murcia.
- Hospital Universitario Santa Lucía de Cartagena.
- Hospital General Universitario de Elche.
- Complejo Hospitalario Torrecárdenas de Almería
All patients with increased temperature and acute abdominal pain, as well as clinical suspicion of AD, will be screened for their potential selection in the study. Basic blood tests (hemogram) and abdominal ultrasound will be performed and these guidelines will be followed: if the results indicate complicated AD, it will be excluded from the study; if uncomplicated DA is suspected, blood CRP will be requested; if CRP is less than 5 mg / dl, it will be included in the study and ambulatory treatment will be indicated; if CRP is greater than 5mg / dl, abdominal CT with intravenous contrast will be requested. Result: uncomplicated DA, it will be included in the study and it will be indicated ambulatory treatment or complicated DA, it will be excluded from the study-; those patients with uncomplicated AD, but with risk factors, hospital admission will be recommended, and they may be offered to participate in the study.
If the patient meets the criteria for admission to the study, the attending physician (surgeon on duty) will inform and invite them to participate and after signing the informed consent, their data will be collected and they will be contacted. the person of the hospital, in charge of guarding the list and randomization codes to assign him the corresponding research group: group 1 (free diet) or group 2 (progressive diet) (Annex III), - this group will be delivered of your printed diet and you will be instructed about it, as well as, to all patients, the annotations of pain control and temperature on ad-hoc sheet. The patient data will be delivered to the investigator / s of the study of each hospital, who will fill in the Data Collection Notebook (DCN) of each patient and program their controls without information of the group to which the patient has been assigned, as In this way, the consultations are carried out with blinding of the evaluator (the investigator who will do the controls will not know to which group the patient has been assigned). They will also be asked a quality of life questionnaire SF-12 (baseline) and they will be asked for a blood test with a complete blood count and CRP for the 3rd day of treatment.
Outpatients will be contacted daily by phone during the first 3 days of treatment by the study investigator and between the 3rd and 4th day will go to outpatient surgery for clinical and analytical control (1st consultation), filling in the DCN. The hospitalized patients will follow the same clinical and analytical control by the plant surgeon and the study investigator, filling in the DCN. They will be asked for new blood tests with CRP for the 7th day of treatment and, in those patients who do not have a colonoscopy in the last 12 months prior to entering the study, an endoscopic study will be requested before 60 days for confirmation of diverticular disease, filling in the DCN. They will be given a new SF-12 quality of life questionnaire that they will fill out on the 7th day of the start of the treatment. They will be cited for a new consultation (2nd consultation) to all patients (outpatients and those who have been hospitalized), 30 days of the beginning of the treatment, with new clinical control and annotation of the last analytical, as well as third and last SF-12 quality of life questionnaire, in the DCN. To conclude, patients who were asked for colonoscopy, will be cited in a final consultation (3rd) 2 months after beginning the treatment with the endoscopic result closing the study, with the last entries in the DCN.
Sample size:
To obtain a power of 80% to reject the null hypothesis Ho: that the difference of proportions p1 and p2 is lower than the non-inferiority limit of -10, and taking into account that the level of significance is 5%, assuming that the proportion of non-treatment failure in both treatment groups is 94.7%, the total number of patients expected to be included in the study is 134 patients, with an expected percentage of dropouts of 5%, which 67 patients will receive treatment through free diet and other 67 patients through progressive diet. The endpoint for the main comparison is the proportion of subjects with a lower treatment failure rate at one month (30 days) of follow-up.
Statistical treatment:
The continuous variables will be summarized using descriptive statistics: mean, standard deviation (SD), median, minimum, maximum, number of observations and number of missing observations. Non-normal continuous data will be presented as maximum, top quartile, median, lowest quartile, minimum and number of observations. The categorical variables will be described using absolute and relative frequencies.
For the comparisons between variables, the bivariate analysis will be used. The scores of each dependent variable will be compared with the independent variables using parametric statistical methods (and nonparametric when the parametric application criteria are not met). When the changes within the same treatment group are analyzed, statistical tests for related or paired samples will be used.
In the event that the variables follow the normal distribution, one or more of the following techniques will be described:
- If a variable is of a quantitative type and the other is categorical, for the comparison of the means with a dichotomous variable, the Student's t test will be used. In cases where the qualitative variable has more than 2 categories, the one-way variance analysis (ANOVA) will be used. In the analysis of the variance of a factor with repeated measures, it will be assumed that the subjects are randomly selected from normal populations with the same variance. Previously, the assumptions of independence, normality and equality of variances will be checked.
In the case that the variables do not follow the normal distribution:
- If one variable is quantitative and the other qualitative, the test to be applied will be the Mann-Whitney U test when the qualitative variable has 2 levels, and the Kruskall-Wallis test if the qualitative measurement is formed by 3 levels or plus.
- If both variables are of the categorical type, a cross-tabulation will be performed (contingency tables) using the Pearson chi-square statistic to test the independence hypothesis or the Fisher test (in 2 x 2 tables) ). An analysis of typed residuals corrected will be carried out in order to interpret the meaning of the association detected.
For the non-inferiority analysis in the main variables, a calculation will be made using the Farrington-Manning score, Miettinen-Nurminen Score and Gart-Nam Score tests, with a significance level of 0.05, and a limit of no- inferiority of 0.10. For the continuous variables, non-inferiority will be evaluated by the difference of means with the Mann-Whitney U and the Wilcoxon test.
All statistical comparisons will be made using statistical tests with a level of significance p = 0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The study is a randomized, multicentric, controlled with active comparator, parallel group, blind to the evaluator, to demonstrate the non-inferiority in the efficacy and therapeutic and safety of the free diet (group 1) compared to the progressive diet (group 2) in the treatment of uncomplicated acute diverticulitis. This study will be carried out on 134 patients with uncomlpicated acute diverticulitis. The subjects will be randomized in a 1: 1 ratio to receive treatment with progressive diet or diet at free demand. The main analysis will take place two months after the start of treatment.
| Arm | Type | Receives |
|---|---|---|
| Free diet | Experimental | Other: Free dietFree diet or free demand, being comparable to the normal or zero hospital diet |
| Progressive diet | Active comparator | Other: Progressive dietProgressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of uncomplicated acute diverticulitis
- Adequate oral tolerance
- Good response to the first emergency treatment measures (analgesics and antibiotic therapy): improvement of pain and decrease in temperature.
- Willing to continue treatment at home under supervision.
- Accept sign informed consent.
Key exclusion criteria (6 listed)
- Acute complicated diverticulitis (from grade Ib of the modified Hinchey Classification).
- No good response to the first emergency treatment measures (analgesics and antibiotics): maintenance or increase of abdominal pain, persistence of fever, oral intolerance or vomiting, clinical worsening.
- Antibiotic treatment for diverticulitis in the previous month.
- Suspicion of colorectal cancer.
- Pregnant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Free dietAlso: Basal dietFree diet or free demand, being comparable to the normal or zero hospital diet | Other | Free diet |
| Progressive dietProgressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day. | Other | Progressive diet |
Primary outcome
Success in the treatment
Time frame: 30 days
Absence of persistence, increase or recurrence of abdominal pain or fever, transition to a stage higher than that of the modified Hinchey classification (requiring radiological drainage and / or surgical treatment), need for hospital admission (for outpatients) and death attributed to this diagnosis.
5 secondary outcomes
Pain score
Time frame: 7 days
Body temperature
Time frame: 7 days
PCR value
Time frame: day 0, 3 and 7
Increase in stage
Time frame: 30 days
Need for hospital admission
Time frame: 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2019.
- Background: PubMed 20485187Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Aiello F. Predictive value of serologic markers of degree of histologic damage in acute uncomplicated colonic diverticulitis. J Clin Gastroenterol. 2010 Nov-Dec;44(10):702-6. doi: 10.1097/MCG.0b013e3181dad979.
- Results publication: PubMed 21928041Klarenbeek BR, de Korte N, van der Peet DL, Cuesta MA. Review of current classifications for diverticular disease and a translation into clinical practice. Int J Colorectal Dis. 2012 Feb;27(2):207-14. doi: 10.1007/s00384-011-1314-5. Epub 2011 Sep 17.
- Results publication: PubMed 23732265Biondo S, Golda T, Kreisler E, Espin E, Vallribera F, Oteiza F, Codina-Cazador A, Pujadas M, Flor B. Outpatient versus hospitalization management for uncomplicated diverticulitis: a prospective, multicenter randomized clinical trial (DIVER Trial). Ann Surg. 2014 Jan;259(1):38-44. doi: 10.1097/SLA.0b013e3182965a11.
- Results publication: PubMed 27941316Reynolds IS, Heaney RM, Khan W, Khan IZ, Waldron R, Barry K. The Utility of Neutrophil to Lymphocyte Ratio as a Predictor of Intervention in Acute Diverticulitis. Dig Surg. 2017;34(3):227-232. doi: 10.1159/000450836. Epub 2016 Dec 10.
- Results publication: PubMed 25665622Makela JT, Klintrup K, Takala H, Rautio T. The role of C-reactive protein in prediction of the severity of acute diverticulitis in an emergency unit. Scand J Gastroenterol. 2015 May;50(5):536-41. doi: 10.3109/00365521.2014.999350. Epub 2015 Feb 9.
- Results publication: PubMed 23088216van de Wall BJ, Draaisma WA, van der Kaaij RT, Consten EC, Wiezer MJ, Broeders IA. The value of inflammation markers and body temperature in acute diverticulitis. Colorectal Dis. 2013 May;15(5):621-6. doi: 10.1111/codi.12072.
- Results publication: PubMed 23807310Nizri E, Spring S, Ben-Yehuda A, Khatib M, Klausner J, Greenberg R. C-reactive protein as a marker of complicated diverticulitis in patients on anti-inflammatory medications. Tech Coloproctol. 2014 Feb;18(2):145-9. doi: 10.1007/s10151-013-1044-5. Epub 2013 Jun 27.
- Results publication: PubMed 9593792Ferzoco LB, Raptopoulos V, Silen W. Acute diverticulitis. N Engl J Med. 1998 May 21;338(21):1521-6. doi: 10.1056/NEJM199805213382107. No abstract available.
- Results publication: PubMed 24859874Jackson JD, Hammond T. Systematic review: outpatient management of acute uncomplicated diverticulitis. Int J Colorectal Dis. 2014 Jul;29(7):775-81. doi: 10.1007/s00384-014-1900-4. Epub 2014 May 25.
- Results publication: PubMed 19231679Martin Gil J, Serralta De Colsa D, Garcia Marin A, Vaquero Rodriguez A, Rey Valcarcel C, Perez Diaz MD, Sanz Sanchez M, Turegano Fuentes F. [Safety and efficiency of ambulatory treatment of acute diverticulitis]. Gastroenterol Hepatol. 2009 Feb;32(2):83-7. doi: 10.1016/j.gastrohep.2008.10.005. Epub 2009 Feb 5. Spanish.
- Results publication: PubMed 28416357Rosado-Cobian R, Blasco-Segura T, Ferrer-Marquez M, Marin-Ortega H, Perez-Dominguez L, Biondo S, Roig-Vila JV. Complicated diverticular disease: Position statement on outpatient management, Hartmann's procedure, laparoscopic peritoneal lavage and laparoscopic approach. Consensus document of the Spanish Association of Coloproctology and the Coloproctology Section of the Spanish Association of Surgeons. Cir Esp. 2017 Aug-Sep;95(7):369-377. doi: 10.1016/j.ciresp.2017.03.008. Epub 2017 Apr 14. English, Spanish.
- Results publication: PubMed 17192220Pelaez N, Pera M, Courtier R, Sanchez J, Gil MJ, Pares D, Grandea L. [Applicability, safety and efficacy of an ambulatory treatment protocol in patients with uncomplicated acute diverticulitis]. Cir Esp. 2006 Dec;80(6):369-72. doi: 10.1016/s0009-739x(06)70989-7. Spanish.
- hospital dietsLink provided by the sponsor.
- Diverticular Disease: An Update on Pathogenesis and Management. Gut LiverLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Diverticulitis
Not yet recruiting
Improving the Treatment of Acute Uncomplicated Diverticulitis in Routine Care
Diverticulitis
RecruitingPhase 2
APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)
Acute Uncomplicated Diverticulitis
Not yet recruitingObservational study
Analysis of the Role of the Microbiota in Diverticular Disease
Diverticular Disease of Colon, Acute Diverticulitis
Not yet recruitingObservational study
Differentiating Right-sided Epiploic Appendagitis From Diverticulitis
Epiploic Appendagitis
Enrolling by invitationObservational study
Shortwave Infrared Surgical Imaging Device Study
Cholecystitis, Cholecystitis, Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jorge A Benavides Buleje, Dr. principal investigator
Hospital General Universitario Reina Sofía de Murcia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Free diet and Progressive diet in people with Diverticulitis and Acute Diverticulitis, run by Hospital General Universitario Reina Sofía de Murcia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Success in the treatment (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03496090, which also lists 41 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2019.